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Abstract
Background Th2 cells play an important role in inter-
mittent allergic rhinitis (IAR). Interleukin (IL)-33
stimulates the production of Th2-associated cytokines.
IL-33 binds to ST2 receptor which is highly expressed on
mast cells and selectively on Th2 cells. IL-33 and ST2
might be involved in the Th2-mediated immune response.
Objective We analyzed the serum level of IL-33 and its
receptor ST2 in patients with IAR sensitive to grass and/or
tree pollen to assess if the serum level of IL-33 and/or ST2
may be a marker of the disease severity.
Methods IL-33, ST2 and total immunoglobulin (Ig) E
were measured in sera of patients with IAR sensitive to
birch and/or grass pollen and in patients with controlled
bronchial asthma and in non-allergic controls. IAR severity
was assessed by total nasal symptom score.
Results Serum levels of IL-33 in patients with IAR were
comparable with patients with bronchial asthma and were
signiﬁcantly higher in patients with IAR (P = 0.0035) and
in patients with bronchial asthma (P = 0.008) than in
controls. Serum levels of IL-33 correlated with disease
severity.
Conclusion Elevated level of IL-33 in sera of patients
with IAR sensitive to tree and/or grass pollen and the
correlation of IL-33 with the disease severity suggest that
IL-33 is involved in the pathogenesis of intermittent
allergic rhinitis.
Keywords ST2  IL-33  Intermittent allergic rhinitis 
Bronchial asthma  IgE  Total nasal symptom score
Introduction
Allergic diseases are thought to be Th2 cell-mediated dis-
eases. Th2 cells produce cytokines, such as interleukin
(IL)-4, IL-5 and IL-13. Recently it has been shown that a
novel cytokine, IL-33, is also involved in the Th2-mediated
immune response and stimulates the production of Th2-
associated cytokines. IL-33 is also a chemoattractant for
human Th2 cells [1]. IL-33 is produced by mast cells after
immunoglobulin (Ig) E-mediated activation and is able to
trigger mast cells to release proinﬂammatory cytokines in
vitro [2–5].
IL-33 is a member of the IL-1 family of cytokines and
binds to two receptors: ST2 (IL-1R1) and IL-1 receptor
accessory protein (IL-1RAP). There are two isoforms of
ST2 proteins: ST2L, a transmembrane form, and soluble
ST2 (sST2), a secreted form that can serve as a decoy
receptor of IL-33. ST2 is highly expressed on mast cells
and selectively on Th2 cells [6–8]. High levels of sST2
have been found in the sera of adults and children with
acute asthma [9, 10]. The IL-33/ST2 signalling pathway
activates airway eosinophils that exacerbate airway
inﬂammation in an autocrine and paracrine manner [11].
This pathway is critical for the progression of IgE-depen-
dent inﬂammation [2]. Mutations in the gene for IL1RL1
(ST2) have been linked to atopic dermatitis and asthma
[12, 13].
IL-33 induces anaphylactic shock in mice and is mark-
edly elevated in the serum of patients during anaphylactic
shock and in atopic human tissue [14]. The role of IL-33 in
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123bronchial asthma has been extensively studied [15, 16].
However, there are less data on the role of IL-33 and its
receptor ST2 in intermittent allergic rhinitis. The serum
level of IL-33 was found to be higher in patients with
Japanese cedar pollinosis [17], However, it has not been
studied in intermittent allergic rhinitis in patients allergic to
other allergens. Moreover, to date the serum level of ST2
has not been analyzed in allergic rhinitis. We therefore
decided to analyze the serum level of IL-33 and the soluble
form of its receptor ST2 in patients with intermittent
allergic rhinitis sensitive to grass and/or tree pollen and to
compare with results in bronchial asthma patients and
healthy controls. Another aim of the study was to assess if
the serum level of IL-33 and/or ST2 may be a marker of the
disease severity.
Methods
Twenty-six patients (14 women, median age 32 years
[25–43]; group IAR) with intermittent allergic rhinitis
sensitive to grass and/or tree pollen were included in the
study. Two control groups were selected. The former
involved 21 patients (12 women, median age 36 years
[27–48]) with controlled bronchial asthma (group AST)
and the latter 27 healthy subjects (15 women, median age
40 years [22–52], group CON) with no signs of allergic
diseases nor any inﬂammatory diseases. The patients were
otherwise healthy, which means that apart from allergic
disease they did not suffered from any other serious
chronic diseases, such as cardiac, renal or gastrointestinal
diseases, and from any acute inﬂammatory disease. These
conditions belonged to the exclusion criteria.
The diagnosis of intermittent allergic rhinitis was based
on clinical history and skin prick test results. Rhinitis was
stated as intermittent according to ARIA criteria [18]. In all
cases, the serum levels of allergen-speciﬁc IgE (as-IgE)
against the most clinically important allergens were esti-
mated to conﬁrm the diagnosis. The patients with
intermittent allergic rhinitis were evaluated in the symp-
tomatic phase of the disease, during the birch pollen season
(end of April, May) or grass pollen season (end of May
until end of July). The diagnosis of controlled bronchial
asthma was based on clinical history, physical ﬁndings and
lung function test results [19]. Patients suffering only from
seasonal asthma were not included into the study.
None of the patients had used systemic corticosteroids
within the last 3 months. The patients with intermittent
allergic rhinitis were allowed to use topical intranasal
steroids and/or nasal decongestants. The patients with
bronchial asthma were allowed to use inhalant glucocorti-
costeroids and short or/and long-acting b2-mimetics. All
patients gave informed consent. The study was approved
by the Local Ethics Committee at the Medical University
of Silesia.
Symptom score in intermittent allergic rhinitis
Patients with intermittent allergic rhinitis evaluated nasal
symptoms using a 4-point scale (Total Nasal Symptom
Score; TNSS) comprising four items: nasal congestion,
nasal itching, sneezing and rhinorrhea, assessed on a 0–3
category scale.
Skin prick tests
Skin prick tests (SPT) were performed according to the
EAACI guidelines [20].
Measurement of serum levels of ST2, IL-33, total
and allergen-speciﬁc IgE
Commercial enzyme-linked immunosorbent assays were
used to measure serum levels of ST2L/IL-1 R4 (R&D
Systems) and IL-33 (GenWay). The assay was performed
using the protocols recommended by the manufacturers.
Total IgE and as-IgE levels were determined by using
ELISA (Allergopharma). Levels of speciﬁc IgE[0.35
(Cclass 1) were considered positive.
Statistical analysis
Results are expressed as median values with interquartile
ranges. Nonparametric tests were used (Mann–Whitney
U rank sum test and Spearman’s correlation test). All
analyses were performed with a software package (Quick
Statistica Pl 5.1). P values less than 0.05 were considered
signiﬁcant.
Results
Serum levels of IL-33 were signiﬁcantly higher in IAR and
AST groups than in CON group (28.5 ng/ml [15–123],
19 ng/ml [15–132], 14 ng/ml [11–44], respectively) and
did not differ between IAR and AST groups (Fig. 1). Serum
levels of ST2 and total IgE were comparable in all groups.
Detailed data are shown in Table 1.
Median TNSS in the IAR group was 8 points (inter-
quartile range: 7–9, range 4–11).
Serum levels of IL-33 signiﬁcantly correlated with
TNSS (rs = 0.54; P = 0.004). The correlations between
serum levels of IL-33 and total IgE and the clinically most
important as-IgE level were non-signiﬁcant. Correlations
between ST2 serum level and TNSS, total IgE and as-IgE
were non-signiﬁcant (data not shown).
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123Discussion
In the present study we found that a serum level of IL-33 is
a marker of Th2-mediated allergic diseases, such as inter-
mittent allergic rhinitis and, moreover, IL-33 is a marker of
the intermittent allergic rhinitis severity. The serum level
of IL-33 was comparable with results found in the asth-
matic group. We failed to show that the form of IL-33
receptor, i.e. ST2, is elevated in serum of patients suffering
from intermittent allergic rhinitis.
Intermittent allergic rhinitis and bronchial asthma
belong to the group of allergic diseases mediated by Th2-
type cytokines, such as IL-4, IL-5, IL-13. These cytokines
are secreted by a subpopulation of T helper cells, called
Th2 cells. It has been recently shown that IL-33 stimulates
Th2 cells to secrete cytokines and is also a chemoattractant
for these cells [1]. Furthermore, IL-33 seems increasingly
to be an important cytokine in many inﬂammatory diseases,
such as inﬂammatory bowel disease, rheumatologic
disorders or central nervous system inﬂammation. On the
other hand, IL-33 has protective effects in cardiovascular
diseases, diabetes mellitus type 2 and obesity [21, 22].
IL-33 mediates its biological effects via interaction with
the two receptors, ST2 (IL-1RL1) and IL-1 receptor
accessory protein. Both of them are expressed on many
immune cells, among them Th2 cells [6–8]. IL-33 acts also
on other cells important in allergic reactions, e.g. mast
cells. IL-33 activates mast cell degranulation through
phospholipase D1 and sphingosine kinase-1 [14]. However,
the presence of preformed IgE is critical for IL-33-induced
mast cell degranulation.
The role of IL-33 has been shown in some allergic
diseases, such as anaphylactic shock, atopic dermatitis or
bronchial asthma [9, 10, 12, 14]. The serum level of IL-33
was studied in a large group of patients suffering from
allergic rhinitis sensitive to Japanese cedar [17]. The serum
level of the cytokine was higher than in controls and this
result is in accordance with our ﬁndings. Moreover, a
positive correlation was found between IL-33 polymor-
phism and Japanese cedar pollinosis. The role of IL-33 was
also conﬁrmed in the pathogenesis of allergic conjunctivitis
using an experimental animal model of sensitization to
ragweed pollen [23]. Matsuba-Kitamura et’al. found that
IL-33 signiﬁcantly increases the capacity of T cells to
produce Th2-type cytokines, increases the inﬁltration of
cervical lymph nodes by eosinophils and Th2 cells, and
that conjunctival tissues constitutively express biologically
active IL-33, suggesting that IL-33 might play a crucial
role in the induction and augmentation of allergic
conjunctivitis.
Interestingly, it has been shown recently that anti-IL-33
antibody has a therapeutic potential for experimental
allergic rhinitis in a murine model of nasal allergy [24].
Anti-IL-33 antibodies relieved nasal symptoms assessed on
the basis of nose-scratching events, and reduced the num-
ber of eosinophils in bronchoalveolar lavage (BAL) and in
nasal cavity inﬁltration and Th2-type cytokines levels in
BAL. Thus one can assume that IL-33 may be a potential
therapeutic target against allergy in humans too.
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Fig. 1 Median values, interquartile and total range of IL-33 serum
levels in intermittent allergic rhinitis and asthma patients and in
controls. IAR intermittent allergic rhinitis group, AST asthma group,
CON control group
Table 1 Serum levels of IL-33, ST2, total and allergen-speciﬁc IgE (median and interquartile ranges)
Intermittent allergic
rhinitic patients
Asthma patients Controls P
IL-33 (ng/ml) 28.5 (15–123) 19 (15–132) 14 (11–44) 0.0035 IAR versus CON,
0.008 AST versus CON
ST2L/IL-1 R4 (ng/ml) 518.5 (293–866) 720 (400–1,090) 590 (457.5–794.5) n.s.
Total IgE (kU/L) 65 (40–160) 49 (30–97) 42 (14–88) n.s.
As-IgE (kU/L) 9.08 (2.84–10.1) n.a. n.a. n.a.
n.s. non-signiﬁcant; n.a. not applicable
IAR intermittent allergic rhinitis group, AST asthma group, CON control group
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123Taken together, the results of our study and previously
published papers conﬁrm the role of IL-33 in Th2-mediated
diseases, such as intermittent allergic rhinitis.
In our study we failed to show the role of ST2 receptor
in intermittent allergic rhinitis based on the estimation of
serum level of this receptor. Previous studies yielded the
evidence of the role of innate immune response in activa-
tion and differentiation of Th2 cells. ST2, being a receptor
for IL-33, constitutes part of this pathway [25]. The role of
the soluble form of ST2 was also conﬁrmed in allergic
asthma [26]. In our study the serum level of ST2 was
comparable both with healthy controls and with asthmatic
patients. This can be explained by the fact that the intensity
of systemic inﬂammation is much lower in intermittent
allergic rhinitis than is found in other allergic diseases,
such as bronchial asthma. It should be noted that in pre-
viously published papers the serum level of ST2 was only
slightly higher in the asymptomatic phase of bronchial
asthma and rose during an asthma attack in adults or in
acute asthma in children [9, 10]. The level of ST2 should
therefore be studied in nasal lavage or in nasal mucosa in
further projects.
In conclusion, we found elevated levels of IL-33 in sera
of patients with intermittent allergic rhinitis sensitive to
tree and/or grass pollen, and that the serum level of IL-33
correlated with the disease severity. Our results suggest
that IL-33 is involved in the pathogenesis of intermittent
allergic rhinitis. The results obtained may provide new
insight into the pathophysiology of the disease and into
novel therapeutic targets.
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